Table 3.

Incidence of cardiac events with other HER2-directed therapies.

Trial	Number of patients in analysis	HER2-directed therapy	Incidence of cardiac events (%)	Definition of cardiac event
Geyer et al. (72)	161	Capecitabine	0.7	Symptomatic decline in LVEF or decrease ≥20% from baseline to below institution’s lower limit of normal
	163	Lapatinib plus Capecitabine	2.4
ALTTO (74)	2097	Trastuzumab alone	0.86	NYHA Class III/IV CHF or cardiac death
	2091	Trastuzumab followed by Lapatinib	0.25
	2093	Trastuzumab concurrent with Lapatinib	0.97
CLEOPATRA (76)	397	Trastuzumab + docetaxel plus placebo	6.6	LVEF decline to <50% with decrease ≥10% from baseline
	407	Trastuzumab + docetaxel plus Pertuzumab	3.8
EMILIA (77)	445	Lapatinib + capecitabine	1.6	LVEF decline to <50% with decrease ≥15% from baseline
	481	T-DM1	1.7